Sterling Medical Devices

sterlingmedicaldevices.com

Sterling Medical Devices specializes in the development and testing of medical devices that includes design, prototyping, software and electronics. Sterling has optimized medical device development for hundreds of companies, enabling a most timely, cost-efficient, and competitive entry to market. Working with products ranging from Class III implantable devices to non-prescription health aids, Sterling provides clients with the tools needed to better manage costs, reduce risk, and stay on schedule to bring their products to market. This dedication is provided to all clients, no matter the company size or stage of development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

DISPERSOL APPOINTS TIM SCOTT NEW PRESIDENT AND CEO; COMPANY CHANGES NAME TO AUSTINPX™, PHARMACEUTICS AND MANUFACTURING

AustinPx | August 29, 2022

news image

DisperSol Technologies, LLC, a specialty pharmaceutical company announced the appointment of Tim Scott as president and chief executive officer of the company. At the same time, the company announced that it is changing its name to AustinPx™, Pharmaceutics and Manufacturing, to better reflect the company’s new direction as a contract development and manufacturing organization. Mr. Scott also joins the board of directors of AustinPx. The hiring of Mr. Scott and the comp...

Read More

RESEARCH

CORIUM ANNOUNCES PUBLICATION OF ADLARITY® CLINICAL TRIAL DATA: DRUG EXPOSURE EQUIVALENT TO ORAL DONEPEZIL WITH FAVORABLE GI SIDE EFFECT PROFILE

Corium, Inc. | September 20, 2022

news image

Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announced publication of its phase 1 healthy volunteer study results for ADLARITY in the peer-reviewed Journal of Alzheimer's Disease. The article, "Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil," reports that Corium's novel once-weekly Alzheimer's dementia treatment del...

Read More

PHARMA TECH

EMERALD HEALTH PHARMACEUTICALS REPORTS DATA SHOWING NOVEL DRUG CANDIDATE IS FIRST-IN-CLASS B55Α/PP2A ACTIVATOR

Emerald Health Pharmaceuticals | October 14, 2022

news image

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...

Read More

PHARMA TECH

NUCLEAI ANNOUNCES A PARTNERSHIP WITH SIRONA DX FOR AI-DRIVEN DISCOVERY OF NOVEL SPATIAL BIOMARKERS IN SOLID TUMORS

Nucleai and Sirona Dx | July 14, 2022

news image

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...

Read More
news image

BUSINESS INSIGHTS

DISPERSOL APPOINTS TIM SCOTT NEW PRESIDENT AND CEO; COMPANY CHANGES NAME TO AUSTINPX™, PHARMACEUTICS AND MANUFACTURING

AustinPx | August 29, 2022

DisperSol Technologies, LLC, a specialty pharmaceutical company announced the appointment of Tim Scott as president and chief executive officer of the company. At the same time, the company announced that it is changing its name to AustinPx™, Pharmaceutics and Manufacturing, to better reflect the company’s new direction as a contract development and manufacturing organization. Mr. Scott also joins the board of directors of AustinPx. The hiring of Mr. Scott and the comp...

Read More
news image

RESEARCH

CORIUM ANNOUNCES PUBLICATION OF ADLARITY® CLINICAL TRIAL DATA: DRUG EXPOSURE EQUIVALENT TO ORAL DONEPEZIL WITH FAVORABLE GI SIDE EFFECT PROFILE

Corium, Inc. | September 20, 2022

Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announced publication of its phase 1 healthy volunteer study results for ADLARITY in the peer-reviewed Journal of Alzheimer's Disease. The article, "Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil," reports that Corium's novel once-weekly Alzheimer's dementia treatment del...

Read More
news image

PHARMA TECH

EMERALD HEALTH PHARMACEUTICALS REPORTS DATA SHOWING NOVEL DRUG CANDIDATE IS FIRST-IN-CLASS B55Α/PP2A ACTIVATOR

Emerald Health Pharmaceuticals | October 14, 2022

Emerald Health Pharmaceuticals Inc. a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis and multiple sclerosis. Titled &...

Read More
news image

PHARMA TECH

NUCLEAI ANNOUNCES A PARTNERSHIP WITH SIRONA DX FOR AI-DRIVEN DISCOVERY OF NOVEL SPATIAL BIOMARKERS IN SOLID TUMORS

Nucleai and Sirona Dx | July 14, 2022

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s leading multiplex assay development expertise to identify novel spatial signatures in high-pl...

Read More